WO2012051633A1 - The treatment of helminthic infections. - Google Patents

The treatment of helminthic infections. Download PDF

Info

Publication number
WO2012051633A1
WO2012051633A1 PCT/ZA2011/000077 ZA2011000077W WO2012051633A1 WO 2012051633 A1 WO2012051633 A1 WO 2012051633A1 ZA 2011000077 W ZA2011000077 W ZA 2011000077W WO 2012051633 A1 WO2012051633 A1 WO 2012051633A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
composition
product
niclosamide
praziquantel
Prior art date
Application number
PCT/ZA2011/000077
Other languages
French (fr)
Inventor
Shoket Latief
Original Assignee
Tri Laz Meds Sa (Pty) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tri Laz Meds Sa (Pty) Ltd filed Critical Tri Laz Meds Sa (Pty) Ltd
Publication of WO2012051633A1 publication Critical patent/WO2012051633A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides

Definitions

  • THIS INVENTION relates to the treatment of helminthic infections.
  • the invention relates to a composition for use in the treatment of helminthic infections, a method of producing a product for the treatment of a patient suffering from a helminthic infection and a product for use in the treatment of a patient suffering from a helminthic infection.
  • composition for use in the treatment of helminthic infections including:
  • the composition includes between about 35% to 40% Praziquantel, between about 31% to 31.25%) Mebendazole and between about 31% to 31.25% Niclosamide in mass percentages relative to one another.
  • the composition includes about 37.5% Praziquantel, about 31.25% Mebendazole and about 31.25% Niclosamide in mass percentages relative to one another.
  • the composition may be provided in a dosage form including about lOOmg to about 200mg Praziquantel, about lOOmg to about 200mg Mebendazole and about lOOmg to about 200mg Niclosamide for administering to persons between the ages of 3 to 8 years.
  • the composition may be provided in a dosage form including about 200mg to about 300mg Praziquantel, about 200mg to about 300mg Mebendazole and about 200mg to about 300mg Niclosamide for administering to persons between the ages of 8 to 13 years.
  • composition may be provided in a dosage form including about 550mg to about 650mg Praziquantel, about 400mg to about 550mg Mebendazole and about 450mg to about 550mg Niclosamide for administering to persons above 13 years of age.
  • the composition may be in tablet form.
  • the composition may be in capsule form.
  • the composition may further include Prednisone.
  • the Prednisone may be in tablet form.
  • the Prednisone may be in capsule form.
  • the composition may further include Metronidazole.
  • the Metronidazole may be in tablet form.
  • the Metronidazole may be in capsule form. According to another aspect of the invention, there is provided a method of producing a product for the treatment of a patient suffering from a helminthic infection, the method including;
  • composition including 31% to 40% Praziquantel; 31% to 35% Mebendazole; and 31% to 35% Niclosamide in mass percentages relative to one another; and
  • the product may further include Prednisone.
  • the Prednisone may be in tablet form.
  • the Prednisone may be in capsule form.
  • the product may further include Metronidazole.
  • the Metronidazole may be in tablet form.
  • the Metronidazole may be in capsule form.
  • the composition includes between about 35% to 40% Praziquantel, between about 31%o to 31.25%) Mebendazole and between about 31% to 31.25%) Niclosamide in mass percentages relative to one another.
  • the composition includes about 37.5% Praziquantel, about 31.25% Mebendazole and about 31.25% Niclosamide in mass percentages relative to one another.
  • a product for use in the treatment of a patient suffering from a helminthic infection including:
  • Mebendazole 31% to 35% and Niclosamide in mass percentages relative to one another; and a package in which the composition is contained.
  • the package may define compartments, the ingredients being contained in different compartments.
  • Each ingredient can be in the form of a tablet.
  • the composition includes between about 35% to 40% Praziquantel, between about 31% to 31.25% Mebendazole and between about 31% to 31.25% Niclosamide in mass percentages relative to one another.
  • the composition includes about 37.5% Praziquantel, about 31.25% Mebendazole and about 31.25% Niclosamide in mass percentages relative to one another.
  • the package may include Prednisone contained separately in one of the compartments.
  • the Prednisone may be in capsule form.
  • the Prednisone may be in tablet form.
  • the package may include Metronidazole contained separately in one of the compartments.
  • the Metronidazole may be in tablet form.
  • the Metronidazole may be in capsule form. Detailed Description of preferred embodiments:
  • a tablet comprising about 600 mg Praziquantel, about 500 mg Mebendazole and about 500 mg Niclosamide is provided.
  • the tablet is produced by providing the ingredients in powder form, then mixing the ingredients together with an appropriate binding agent and moulding the mixed ingredients under pressure to form a pressed tablet. Instead, the ingredients can be provided in capsule form.
  • the tablet is administered to a patient in the treatment of helminthic infections, such as, Human Immunodeficiency Virus (HIV) and the like, for example.
  • helminthic infections such as, Human Immunodeficiency Virus (HIV) and the like
  • the pressed tablet is administered orally.
  • the dosage varies from patient to patient depending on the age and body mass of the patient.
  • the composition is provided in a dosage form including about lOOmg to about 200mg Praziquantel, about lOOmg to about 200mg Mebendazole and about lOOmg to about 200mg Niclosamide for administering to persons between the ages of 3 to 8 years.
  • the composition is provided in a dosage form including about 200mg to about 300mg Praziquantel, about 200mg to about 300mg Mebendazole and about 200mg to about 300mg Niclosamide for administering to persons between the ages of 8 to 13 years.
  • the composition is provided in a dosage form including about 550mg to about 650mg Praziquantel, about 400mg to about 550mg Mebendazole and about 450mg to about 550mg Niclosamide for administering to persons above 13 years of age.
  • the composition is provided in a dosage form including about 600mg Praziquantel, about 500mg Mebendazole and about 500mg Niclosamide for administering to persons above 13 years of age.
  • the composition is administered in a way in which the ingredients are administered in the form of separate tablets.
  • a tablet containing about lOOmg to about 200mg Praziquantel, a tablet containing about lOOmg to about 200mg Mebendazole and a tablet containing about lOOmg to about 200mg Niclosamide is provided for administering to persons between the ages of 3 to 8 years.
  • a tablet including about 200mg to about 300mg Praziquantel, a tablet containing about 200mg to about 300mg Mebendazole and a tablet containing about 200mg to about 300mg Niclosamide is provided for administering to persons between the ages of 8 to 13 years.
  • a tablet including about 550mg to about 650mg Praziquantel, a tablet containing about 400mg to about 550mg Mebendazole and a tablet containing about 450mg to about 550mg Niclosamide is provided for administering to persons above 13 years of age.
  • a tablet including about 600mg Praziquantel, a tablet containing about 500mg Mebendazole and a tablet containing about 500mg Niclosamide is provided for administering to persons above 13 years of age.
  • the tablets can be provided in separate containers held in a common package, or box. Eight adults were placed under treatment by administering 600mg Praziquantel, 500mg Mebendazole and 500mg Niclosamide. Three days before commencement of treatment, the following readings were obtained:
  • the treatment can be enhanced with Metronidazole and Prednisone.
  • the treatment can be provided in blister pack form.
  • the blister pack can be printed with Monday, Tuesday, Wednesday, Thursday, Friday and Saturday, to indicated daily treatments to a user.
  • the Praziquantel, the Mebendazole and the Niclosamide can be provided in separate containers, such as, packets, or bottles, or the like for example, in which the containers are packaged in a common package.
  • the Praziquantel, the Mebendazole and the Niclosamide can then be in tablet form, or capsule form, each containing an amount of Praziquantel, Mebendazole and Niclosamide such that when one of each tablet is administered the dosage of the separate ingredients fall within the range of about 35% to 40% Praziquantel, about 31% to 31.25% Mebendazole and about 31% to 31.25% Niclosamide in mass percentages relative to one another.
  • the dosage is about 600mg Praziquantel, about 500mg Mebendazole and about 500mg Niclosamide.
  • the package can include separate containers containing Metronidazole and Prednisone. The ingredients can all then be in tablet, or capsule, form.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides for a composition for use in the treatment of helminthic infections. The composition includes between 31% to 40% Praziquantel, between 31% to 35% Mebendazole and between 31% to 35% Niclosamide, in mass percentages relative to one another. The invention further provides for a method of producing a product for the treatment of an helminthic infection and to a product for the treatment of an helminthic infection.

Description

Title:
The treatment of helminthic infections.
Field of the invention:
THIS INVENTION relates to the treatment of helminthic infections. In particular, the invention relates to a composition for use in the treatment of helminthic infections, a method of producing a product for the treatment of a patient suffering from a helminthic infection and a product for use in the treatment of a patient suffering from a helminthic infection.
Background of the invention:
The treatment of helminthic infections. Summary of the invention:
According to a first aspect of the invention, there is provided a composition for use in the treatment of helminthic infections, the composition including:
31% to 40% Praziquantel;
31 % to 35% Mebendazole; and
31% to 35% Niclosamide in mass percentages relative to one another.
Advantageously, the composition includes between about 35% to 40% Praziquantel, between about 31% to 31.25%) Mebendazole and between about 31% to 31.25% Niclosamide in mass percentages relative to one another.
Ideally, the composition includes about 37.5% Praziquantel, about 31.25% Mebendazole and about 31.25% Niclosamide in mass percentages relative to one another.
The composition may be provided in a dosage form including about lOOmg to about 200mg Praziquantel, about lOOmg to about 200mg Mebendazole and about lOOmg to about 200mg Niclosamide for administering to persons between the ages of 3 to 8 years. The composition may be provided in a dosage form including about 200mg to about 300mg Praziquantel, about 200mg to about 300mg Mebendazole and about 200mg to about 300mg Niclosamide for administering to persons between the ages of 8 to 13 years. The composition may be provided in a dosage form including about 550mg to about 650mg Praziquantel, about 400mg to about 550mg Mebendazole and about 450mg to about 550mg Niclosamide for administering to persons above 13 years of age.
The composition may be in tablet form.
The composition may be in capsule form. The composition may further include Prednisone. The Prednisone may be in tablet form. The Prednisone may be in capsule form. The composition may further include Metronidazole.
The Metronidazole may be in tablet form.
The Metronidazole may be in capsule form. According to another aspect of the invention, there is provided a method of producing a product for the treatment of a patient suffering from a helminthic infection, the method including;
providing a composition including 31% to 40% Praziquantel; 31% to 35% Mebendazole; and 31% to 35% Niclosamide in mass percentages relative to one another; and
producing a product containing the composition in a form suitable for human consumption.
Producing a product containing the composition in a form suitable for human consumption may include producing a tablet. Producing a product containing the composition in a form suitable for human consumption may include producing a capsule.
The product may further include Prednisone.
The Prednisone may be in tablet form. The Prednisone may be in capsule form. The product may further include Metronidazole. The Metronidazole may be in tablet form. The Metronidazole may be in capsule form.
Advantageously, the composition includes between about 35% to 40% Praziquantel, between about 31%o to 31.25%) Mebendazole and between about 31% to 31.25%) Niclosamide in mass percentages relative to one another. Ideally, the composition includes about 37.5% Praziquantel, about 31.25% Mebendazole and about 31.25% Niclosamide in mass percentages relative to one another.
According to another aspect of the invention, there is provided a product for use in the treatment of a patient suffering from a helminthic infection, the product including:
a composition defining ingredients of 31% to 40% Praziquantel, 31% to 35%
Mebendazole, 31% to 35% and Niclosamide in mass percentages relative to one another; and a package in which the composition is contained.
The package may define compartments, the ingredients being contained in different compartments.
Each ingredient can be in the form of a tablet.
Each ingredient can be in the form of a capsule. Advantageously, the composition includes between about 35% to 40% Praziquantel, between about 31% to 31.25% Mebendazole and between about 31% to 31.25% Niclosamide in mass percentages relative to one another. Ideally, the composition includes about 37.5% Praziquantel, about 31.25% Mebendazole and about 31.25% Niclosamide in mass percentages relative to one another.
The package may include Prednisone contained separately in one of the compartments. The Prednisone may be in capsule form.
The Prednisone may be in tablet form.
The package may include Metronidazole contained separately in one of the compartments.
The Metronidazole may be in tablet form. The Metronidazole may be in capsule form. Detailed Description of preferred embodiments:
Embodiments of the invention will now be described, by way of example.
A tablet comprising about 600 mg Praziquantel, about 500 mg Mebendazole and about 500 mg Niclosamide is provided. The tablet is produced by providing the ingredients in powder form, then mixing the ingredients together with an appropriate binding agent and moulding the mixed ingredients under pressure to form a pressed tablet. Instead, the ingredients can be provided in capsule form.
In use, the tablet is administered to a patient in the treatment of helminthic infections, such as, Human Immunodeficiency Virus (HIV) and the like, for example. Typically, the pressed tablet is administered orally. Typically, the dosage varies from patient to patient depending on the age and body mass of the patient. Typically, the composition is provided in a dosage form including about lOOmg to about 200mg Praziquantel, about lOOmg to about 200mg Mebendazole and about lOOmg to about 200mg Niclosamide for administering to persons between the ages of 3 to 8 years. The composition is provided in a dosage form including about 200mg to about 300mg Praziquantel, about 200mg to about 300mg Mebendazole and about 200mg to about 300mg Niclosamide for administering to persons between the ages of 8 to 13 years. The composition is provided in a dosage form including about 550mg to about 650mg Praziquantel, about 400mg to about 550mg Mebendazole and about 450mg to about 550mg Niclosamide for administering to persons above 13 years of age. Typically, the composition is provided in a dosage form including about 600mg Praziquantel, about 500mg Mebendazole and about 500mg Niclosamide for administering to persons above 13 years of age. In another embodiment, the composition is administered in a way in which the ingredients are administered in the form of separate tablets. In such a case, a tablet containing about lOOmg to about 200mg Praziquantel, a tablet containing about lOOmg to about 200mg Mebendazole and a tablet containing about lOOmg to about 200mg Niclosamide is provided for administering to persons between the ages of 3 to 8 years. A tablet including about 200mg to about 300mg Praziquantel, a tablet containing about 200mg to about 300mg Mebendazole and a tablet containing about 200mg to about 300mg Niclosamide is provided for administering to persons between the ages of 8 to 13 years. A tablet including about 550mg to about 650mg Praziquantel, a tablet containing about 400mg to about 550mg Mebendazole and a tablet containing about 450mg to about 550mg Niclosamide is provided for administering to persons above 13 years of age. Typically, a tablet including about 600mg Praziquantel, a tablet containing about 500mg Mebendazole and a tablet containing about 500mg Niclosamide is provided for administering to persons above 13 years of age. The tablets can be provided in separate containers held in a common package, or box. Eight adults were placed under treatment by administering 600mg Praziquantel, 500mg Mebendazole and 500mg Niclosamide. Three days before commencement of treatment, the following readings were obtained:
Patient 1: Viral load 720611 cps/mL
Patient 2: Viral load 371336 cps/mL
Patient 3: Viral load 364564 cps/mL
Patient 4: Viral load 186524 cps/mL
Patient 5: Viral load 89875 cps/mL
Patient 6: Viral load 166169 cps/mL Patient 7: Viral load 106110 cps/mL
Patient 8: Viral load 22757 cps/mL
Patient 9: Viral load 168611 cps/mL
Patient 10: Viral load 198271 cps/mL
Patient 11: Viral load 121453 cps/mL
After thirty days of treatment, the following results were obtained:
Patient 1: Viral load 440458cps/mL
Patient 2: Viral load 278401 cps/mL
Patient 3: Viral load 262486 cps/mL
Patient 4: Viral load 113780 cps/mL
Patient 5: Viral load 62570 cps/mL
Patient 6: Viral load 235 cps/mL
Patient 7: Viral load 76398 cps/mL
Patient 8: Viral load 15960 cps/mL
After forty days of treatment, the following results were obtained:
Patient 9: Viral load
Patient 10: Viral load
Patient 10: Viral load
After sixty days of treatment, the following results were obtained:
Patient 1: Viral load 209214 cps/mL
Patient 2: Viral load 208813 cps/mL
Patient 3: Viral load 196864 cps/mL
Patient 4: Viral load 82490 cps/mL
Patient 5: Viral load 17094 cps/mL
Patient 6: Viral load 188 cps/mL
Patient 7: Viral load 46880 cps/mL
Patient 8: Viral load 11970 cps/mL After ninety days of treatment, the following results were obtained:
Patient 1: Viral load 124358 cps/mL
Patient 2: Viral load 96112 cps/mL
Patient 3: Viral load 85710 cps/mL
Patient 4: Viral load 32391 cps/mL
Patient 5: Viral load 5823 cps/mL
Patient 6: Viral load 1782 cps/mL
Patient 7: Viral load 33720 cps/mL
Patient 8: Viral load 7884 cps/mL
Dosage for children using a blister pack containing the three active ingredients separately:
3 to 8 years Actual dosage: 150 mg Praziquantel
125 mg Mebendazole
125 mg Niclosamide
It has been found that the ratio of lOOmg to 200mg Praziquantel, lOOmg to 200mg Mebendazole and lOOmg to 200mg Niclosamide yield satisfactory results for children in this age group.
8 to 13 years Actual dosage: 300 mg Praziquantel
250 mg Mebendazole
250 mg Niclosamide It has been found that the ratio of 200mg to 300mg Praziquantel, 200mg to 300mg Mebendazole and 200mg to 300mg Niclosamide yield satisfactory results for children in this age group.
The treatment can be enhanced with Metronidazole and Prednisone. The treatment can be provided in blister pack form. The blister pack can be printed with Monday, Tuesday, Wednesday, Thursday, Friday and Saturday, to indicated daily treatments to a user.
In another embodiment, the Praziquantel, the Mebendazole and the Niclosamide can be provided in separate containers, such as, packets, or bottles, or the like for example, in which the containers are packaged in a common package. The Praziquantel, the Mebendazole and the Niclosamide can then be in tablet form, or capsule form, each containing an amount of Praziquantel, Mebendazole and Niclosamide such that when one of each tablet is administered the dosage of the separate ingredients fall within the range of about 35% to 40% Praziquantel, about 31% to 31.25% Mebendazole and about 31% to 31.25% Niclosamide in mass percentages relative to one another. Typically, when one of each tablet, or capsule, is administered, the dosage is about 600mg Praziquantel, about 500mg Mebendazole and about 500mg Niclosamide. The package can include separate containers containing Metronidazole and Prednisone. The ingredients can all then be in tablet, or capsule, form.

Claims

Claims: 1. A composition for use in the treatment of helminthic infections, the composition including:
31% to 40% Praziquantel;
31% to 35% Mebendazole; and
31% to 35% Niclosamide in mass percentages relative to one another.
2. The composition for use in the treatment of helminthic infections as claimed in claim 1, in which the composition includes between about 35% to 40% Praziquantel, between about 31% to 31.25% Mebendazole and between about 31% to 31.25% Niclosamide in mass percentages relative to one another.
3. The composition for use in the treatment of helminthic infections as claimed in claim 2, in which the composition includes about 37.5% Praziquantel, about 31.25% Mebendazole and about 31.25% Niclosamide in mass percentages relative to one another.
4. The composition for use in the treatment of helminthic infections as claimed in any one of claims 1 to 3 inclusive, in which he composition is provided in a dosage form including about lOOmg to about 200mg Praziquantel, about lOOmg to about 200mg Mebendazole and about lOOmg to about 200mg Niclosamide for administering to persons between the ages of 3 to 8 years.
5. The composition for use in the treatment of helminthic infections as claimed in any one of claims 1 to 3 inclusive, in which the composition is provided in a dosage form including about 200mg to about 300mg Praziquantel, about 200mg to about 300mg Mebendazole and about 200mg to about 300mg Niclosamide for administering to persons between the ages of 8 to 13 years.
6. The composition for use in the treatment of helminthic infections as claimed in any one of claims 1 to 3 inclusive, in which the composition is provided in a dosage form including about 550mg to about 650mg Praziquantel, about 400mg to about 550mg Mebendazole and about 450mg to about 550mg Niclosamide for administering to persons above 13 years of age.
7. The composition for use in the treatment of helminthic infections as claimed in any one of the preceding claims in which the composition further includes Prednisone.
8. The composition for use in the treatment of helminthic infections as claimed in any one of the preceding claims in which the composition further includes Metronidazole.
9. A method of producing a product for the treatment of a patient suffering from a helminthic infection, the method including;
providing a composition including 31% to 40% Praziquantel; 31% to 35% Mebendazole; and 31% to 35% Niclosamide in mass percentages relative to one another; and
producing a product containing the composition in a form suitable for human consumption.
10. The method of producing a product for the treatment of a patient suffering from a helminthic infection as claimed in claim 9, in which the product further includes Prednisone.
11. The method of producing a product for the treatment of a patient suffering from a helminthic infection as claimed in claim 9 or claim 10, in which the product further includes Metronidazole.
12. The method of producing a product for the treatment of a patient suffering from a helminthic infection as claimed in any one of claims 9 to 11 inclusive, in which the composition includes between about 35% to 40% Praziquantel, between about 31% to 31.25% Mebendazole and between about 31% to 31.25% Niclosamide in mass percentages relative to one another.
\
13. The method of producing a product for the treatment of a patient suffering from a helminthic infection as claimed in claim 12, in which the composition includes about 37.5%
Praziquantel, about 31.25% Mebendazole and about 31.25% Niclosamide in mass percentages relative to one another.
14. A product for use in the treatment of a patient suffering from a helminthic infection, the product including:
a composition defining ingredients of 31% to 40% Praziquantel, 31% to 35% Mebendazole, 31% to 35% and Niclosamide in mass percentages relative to one another; and a package in which the composition is contained.
15. The product for use in the treatment of a patient suffering from a helminthic infection as claimed in claim 14, in which the package defines compartments, the ingredients being contained in different compartments.
16. The product for use in the treatment of a patient suffering from a helminthic infection as claimed in claim 15, in which each ingredient is in a form selected from the group consisting of a tablet form and a capsule form.
17. The product for use in the treatment of a patient suffering from a helminthic infection as claimed in any one of claims 14 to 16 inclusive, in which the composition includes between about 35% to 40% Praziquantel, between about 31% to 31.25% Mebendazole and between about 31% to 31.25% Niclosamide in mass percentages relative to one another.
18. The product for use in the treatment of a patient suffering from a helminthic infection as claimed in claim 17, in which the composition includes about 37.5% Praziquantel, about 31.25% Mebendazole and about 31.25% Niclosamide in mass percentages relative to one another.
19. The product for use in the treatment of a patient suffering from a helminthic infection as claimed in any one of claims 14 to 18 inclusive, in which the package includes Prednisone contained separately in one of the compartments.
20. The product for use in the treatment of a patient suffering from a helminthic infection as claimed in claim 19, in which the Prednisone is in a form selected from the group consisting of a tablet form and a capsule form.
21. The product for use in the treatment of a patient suffering from a helminthic infection as claimed in any one of claims 14 to 20 inclusive, in which the package includes Metronidazole contained separately in one of the compartments 22. The product for use in the treatment of a patient suffering from a helminthic infection as claimed in claim 21, in which the Metronidazole is in a form selected from the group consisting of a tablet form and a capsule form.
PCT/ZA2011/000077 2010-10-15 2011-10-13 The treatment of helminthic infections. WO2012051633A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA201007381 2010-10-15
ZA2010/07381 2010-10-15

Publications (1)

Publication Number Publication Date
WO2012051633A1 true WO2012051633A1 (en) 2012-04-19

Family

ID=45938746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ZA2011/000077 WO2012051633A1 (en) 2010-10-15 2011-10-13 The treatment of helminthic infections.

Country Status (1)

Country Link
WO (1) WO2012051633A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013093790A1 (en) * 2011-12-22 2013-06-27 Shoket Latief A composition for reducing an hiv viral load comprising praziquantel, niclosamide and albendazole

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047842A1 (en) * 2002-11-28 2004-06-10 Moore, Bronwyn Treatment of immune system dysfunction
WO2009118706A2 (en) * 2008-03-26 2009-10-01 Tri Laz Meds (Proprietary) Limited The treatment of helminthic infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047842A1 (en) * 2002-11-28 2004-06-10 Moore, Bronwyn Treatment of immune system dysfunction
WO2009118706A2 (en) * 2008-03-26 2009-10-01 Tri Laz Meds (Proprietary) Limited The treatment of helminthic infections

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013093790A1 (en) * 2011-12-22 2013-06-27 Shoket Latief A composition for reducing an hiv viral load comprising praziquantel, niclosamide and albendazole

Similar Documents

Publication Publication Date Title
US20200113884A1 (en) Method of providing pirfenidone therapy to a patient
US20230081837A1 (en) Products of manufacture and methods for treating, ameliorating or preventing coronavirus infection
HUP0402154A2 (en) Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus
EA017764B8 (en) Pharmaceutical composition, method for preparation thereof and method for treating antiviral diseases using same
WO2004080428A3 (en) Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
EA201001592A1 (en) HOMEOPATHIC MEDICINE
RU2007101686A (en) COMBINED COMPOSITION
WO2002045686A3 (en) Pharmaceutical paste comprising an acid-labile active ingredient
WO2012051633A1 (en) The treatment of helminthic infections.
WO2008079343A3 (en) Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients
AU2008253776A8 (en) Agent, pharmaceutical composition, and method for treating the ethyl alcohol and/or narcotic dependence
US10391139B2 (en) Blood pressure reduction with dietary supplements
KR20180074707A (en) Low dose oral dipyridamole compositions and uses thereof
WO2011108882A3 (en) Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient
WO2009118706A2 (en) The treatment of helminthic infections
US20230089090A1 (en) Composition for Treating Viral Infections
FR2975299A1 (en) USE OF SECNIDAZOLE IN THE TREATMENT OF DENTAL INFECTIONS
CN115916204A (en) Methods for treating RNA viral infections including COVID-19 (SARS-CoV-2)
Label FDA Label for Rimantalist
CN109953325A (en) Improve the health food of anoxia endurance
WO2017089465A1 (en) Nutritional supplement formulation for use in tattooing
TH74674A (en) An aerosol antiperspirant mixture containing inert silicones
CZ12907U1 (en) Compound pharmaceutical preparation intended for treating hypertension and hyperlipoproteinemia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11833563

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11833563

Country of ref document: EP

Kind code of ref document: A1